IQVIA Holdings Inc. (IQV) Stock Price & Analysis
IQVIA Holdings Inc. (IQV) closed at USD 278.32 on Thursday, October 22, 2026, up 0.61% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 278.32; the Oct 22, 2026 session ranged USD 273.8–282.98 on volume of 1,672,402 shares. Market capitalization is —, with a 52-week range of USD 154.5–282.98 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.
Also available as compact Markdown for AI agents: nexqual.com/IQV.md
Key facts (IQV)
- Last four reported quarters (through Jun 30, 2026): revenue $17.0B, net income $1.38B (8.1% margin), free cash flow $2.18B (SEC filings).
- Valuation: P/E 33.3x (avg 28.9x at the last 3 fiscal year-ends), EV/EBITDA 17.7x, net debt $13.9B.
- 4 of 80 tracked superinvestors hold IQV (13F, Q2 2026): 1 new, 1 added, 0 reduced, 2 unchanged.
- Insider open-market sales, last ~7 months: 6 Form 4 filings, $29.9M; 6 not under a Rule 10b5-1 plan ($29.9M); 1 by opportunistic insiders (1 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.95 on a 1–5 scale) (21 analysts), mean target USD 302.67 (range 268–345).
- Total return with dividends: 1Y +26.6% vs S&P 500 +14.9%; 5Y +8.3% vs S&P 500 +80.3%.
- Next earnings: 2026-10-27, EPS estimate USD 3.28, revenue estimate $4.37B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (IQV)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $13.9B | $14.4B | $15.0B | $15.4B | $16.3B | $17.0B |
| Operating income | $1.39B | $1.80B | $1.98B | $2.20B | $2.18B | $2.20B |
| Net income | $966M | $1.09B | $1.36B | $1.37B | $1.36B | $1.38B |
| EPS (diluted) | $4.95 | $5.72 | $7.29 | $7.49 | $7.84 | — |
| Free cash flow | $2.30B | $1.59B | $1.50B | $2.11B | $2.05B | $2.18B |
| Operating margin | 10.0% | 12.5% | 13.2% | 14.3% | 13.4% | 13.0% |
| Net margin | 7.0% | 7.6% | 9.1% | 8.9% | 8.3% | 8.1% |
| Revenue growth | +22.1% | +3.9% | +4.0% | +2.8% | +5.9% | — |
| Cash + short-term investments | $1.48B | $1.31B | $1.50B | $1.84B | $2.14B | — |
| Total debt | $12.1B | $12.7B | $13.7B | $14.0B | $15.7B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (IQV)
P/E 33.3x · P/S 2.7x · EV/EBITDA 17.7x · EV/Sales 3.5x · P/FCF 21.0x · P/B 7.4x · FCF yield 4.77% · Earnings yield 3.00% · Buyback yield (TTM) 2.54% · Net debt $13.9B · EV $59.7B
P/E at fiscal year-ends: Dec 2025 28.8x, Dec 2024 26.2x, Dec 2023 31.7x.
Superinvestors (SEC 13F-HR, Q2 2026) (IQV)
4 of 80 tracked investors hold IQV. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Bill Nygren | Oakmark Funds | 3.13% | $2.35B | Unchanged |
| Greenhaven Associates | 1.71% | $148M | New position | |
| Vulcan Value Partners | 1.53% | $50.2M | Added +4.7% | |
| Thomas Gayner | Markel Group | 0.07% | $9.1M | Unchanged |
Insider sales (SEC Form 4, open-market, last ~7 months) (IQV)
0 of 6 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | Berkshire James G. | See Remarks | 2,668 | $697K | 24.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-03 | Staub W Richard | See Remarks | 5,500 | $1.3M | 29.2% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-07-31 | Patel Bhavik | See Remarks | 1,855 | $436K | 57.9% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-07-29 | Sherbet Eric | See Remarks | 5,000 | $1.2M | 19.2% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-07-29 | Cherofsky Keriann | See Remarks | 558 | $137K | 15.7% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-07-29 | Bousbib Ari | See Remarks | 106,279 | $26.1M | 7.2% | No | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (IQV)
Consensus Buy (mean 1.95 on a 1–5 scale), 21 analysts; mean target USD 302.67 (low 268, high 345).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Stifel | Target raised | Buy | $276 → $303 |
| 2026-10-07 | Mizuho | Target raised | Outperform | $275 → $300 |
| 2026-10-07 | Barclays | Target raised | Overweight | $275 → $300 |
| 2026-09-29 | RBC Capital | Target raised | Outperform | $247 → $319 |
| 2026-09-28 | Truist Securities | Target raised | Buy | $300 → $329 |
| 2026-09-17 | Morgan Stanley | Target raised | Equal-Weight | $240 → $270 |
| 2026-07-29 | JP Morgan | Target raised | Overweight | $225 → $285 |
| 2026-07-29 | Stifel | Target raised | Buy | $220 → $276 |
| 2026-07-29 | TD Cowen | Target raised | Buy | $233 → $288 |
| 2026-07-29 | RBC Capital | Target raised | Outperform | $221 → $247 |
| 2026-07-29 | BMO Capital | Target raised | Outperform | $210 → $270 |
| 2026-07-29 | Baird | Target raised | Outperform | $252 → $287 |
Total return (dividends reinvested) (IQV)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +26.6% | +8.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +26.7% | +1.6% |
| Volatility (annualized) | 40.2% | 35.7% |
| Max drawdown | -35.9% (Jan 2026→Apr 2026) | -51.4% (Dec 2021→May 2025) |
IQV revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Research & Development Solutions | $2.58B | 59.0% | +8.8% |
| Commercial Solutions | $1.79B | 41.0% | +8.6% |
| Total revenue | $4.37B | 100% | — |
IQV revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Americas | $2.04B | 46.7% | +5.4% |
| Europe and Africa | $1.41B | 32.3% | +13.5% |
| Asia-Pacific | $920.0M | 21.1% | +9.4% |
| Total revenue | $4.37B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
IQV suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | Charles River Laboratories | “The peer group consists of Charles River Laboratories, Inc., Fortrea Holdings Inc., ICON plc, Medpace Holdings Inc., S&P Global Inc., Danaher Corporation and Thermo Fisher Scientific Inc. The companies in our peer group are publicly traded information services, information technology or clinical research companies, and thus share similar business model characteristics to IQVIA, or provide services to similar custo…” |
| Customer | Fortrea Holdings Inc. (FTRE) | “The peer group consists of Charles River Laboratories, Inc., Fortrea Holdings Inc., ICON plc, Medpace Holdings Inc., S&P Global Inc., Danaher Corporation and Thermo Fisher Scientific Inc. The companies in our peer group are publicly traded information services, information technology or clinical research companies, and thus share similar business model characteristics to IQVIA, or provide services to similar custo…” |
| Customer | ICON PLC (ICLR) | “The peer group consists of Charles River Laboratories, Inc., Fortrea Holdings Inc., ICON plc, Medpace Holdings Inc., S&P Global Inc., Danaher Corporation and Thermo Fisher Scientific Inc. The companies in our peer group are publicly traded information services, information technology or clinical research companies, and thus share similar business model characteristics to IQVIA, or provide services to similar custo…” |
| Customer | Medpace Holdings, Inc. (MEDP) | “The peer group consists of Charles River Laboratories, Inc., Fortrea Holdings Inc., ICON plc, Medpace Holdings Inc., S&P Global Inc., Danaher Corporation and Thermo Fisher Scientific Inc. The companies in our peer group are publicly traded information services, information technology or clinical research companies, and thus share similar business model characteristics to IQVIA, or provide services to similar custo…” |
| Customer | S&P Global Inc. (SPGI) | “The peer group consists of Charles River Laboratories, Inc., Fortrea Holdings Inc., ICON plc, Medpace Holdings Inc., S&P Global Inc., Danaher Corporation and Thermo Fisher Scientific Inc. The companies in our peer group are publicly traded information services, information technology or clinical research companies, and thus share similar business model characteristics to IQVIA, or provide services to similar custo…” |
| Customer | Danaher | “The peer group consists of Charles River Laboratories, Inc., Fortrea Holdings Inc., ICON plc, Medpace Holdings Inc., S&P Global Inc., Danaher Corporation and Thermo Fisher Scientific Inc. The companies in our peer group are publicly traded information services, information technology or clinical research companies, and thus share similar business model characteristics to IQVIA, or provide services to similar custo…” |
| Customer | THERMO FISHER SCIENTIFIC INC. (TMO) | “The peer group consists of Charles River Laboratories, Inc., Fortrea Holdings Inc., ICON plc, Medpace Holdings Inc., S&P Global Inc., Danaher Corporation and Thermo Fisher Scientific Inc. The companies in our peer group are publicly traded information services, information technology or clinical research companies, and thus share similar business model characteristics to IQVIA, or provide services to similar custo…” |
| Partner | General | “Our IISF is based on relevant industry frameworks and laws, including, but not limited to National Institute of Standards and Technology ("NIST"), Good Practices Quality Guidelines (GxP), Health Information Trust Alliance (HITRUST), the ISMS Family of Standards (ISO 27000 family), Control Objectives for Information Technologies (COBIT), the EU General Data Protection Regulation (GDPR), and the Health Insurance Por…” |
| Competitor | Accenture (ACN) | “Our offerings compete with various firms, including Accenture, Aetion (a Datavant company), Panalgo (a Norstella company), Cognizant Technology Solutions, Deloitte, Pharmaceutical Product Development, Inc. (part of Thermo Fisher Scientific Inc.), Relx, IBM, Infosys, Oracle Health, McKinsey, NielsenIQ, Optum Insight (part of UnitedHealth Group), Parexel International Corporation, Press Ganey, RTI Health Solutions, …” |
| Competitor | IBM (IBM) | “Our offerings compete with various firms, including Accenture, Aetion (a Datavant company), Panalgo (a Norstella company), Cognizant Technology Solutions, Deloitte, Pharmaceutical Product Development, Inc. (part of Thermo Fisher Scientific Inc.), Relx, IBM, Infosys, Oracle Health, McKinsey, NielsenIQ, Optum Insight (part of UnitedHealth Group), Parexel International Corporation, Press Ganey, RTI Health Solutions, …” |
| Competitor | Oracle (ORCL) | “Our offerings compete with various firms, including Accenture, Aetion (a Datavant company), Panalgo (a Norstella company), Cognizant Technology Solutions, Deloitte, Pharmaceutical Product Development, Inc. (part of Thermo Fisher Scientific Inc.), Relx, IBM, Infosys, Oracle Health, McKinsey, NielsenIQ, Optum Insight (part of UnitedHealth Group), Parexel International Corporation, Press Ganey, RTI Health Solutions, …” |
| Competitor | UnitedHealth (UNH) | “Our offerings compete with various firms, including Accenture, Aetion (a Datavant company), Panalgo (a Norstella company), Cognizant Technology Solutions, Deloitte, Pharmaceutical Product Development, Inc. (part of Thermo Fisher Scientific Inc.), Relx, IBM, Infosys, Oracle Health, McKinsey, NielsenIQ, Optum Insight (part of UnitedHealth Group), Parexel International Corporation, Press Ganey, RTI Health Solutions, …” |
Quoted from the company's 10-K filed Feb 17, 2026.
Companies that name IQV in their SEC reports
| Relationship to IQV | Company | Filing | Sentence |
|---|---|---|---|
| partner | Cingulate Inc. (CING) | 10-K Mar 18, 2026 | “November 2025, we entered into a into a licensing and services master agreement with IQVIA Inc. ("IQVIA") to partner in the” |
| customer | Viatris Inc (VTRS) | 10-K Feb 26, 2026 | “Unless otherwise indicated, industry data included in this Item 1 are sourced from IQVIA Holdings Inc. and are for the twelve months ended November 2025 and Viatris product and other company data included in this Item 1 are from internal sources and are as of November 30, 2025.” |
| supplier | Fortrea Holdings Inc. (FTRE) | 10-K Feb 26, 2026 | “The Peer Group consists of Charles River Laboratories Inc., ICON plc, Medpace Holdings, Inc., IQVIA Holdings Inc. and Thermo Fisher Scientific Inc. The companies in our Peer Group are publicly traded companies that share similar business model characteristics to Fortrea, or provide services to similar customers as Fortrea.” |
IQV company outlook (results filed Jul 28, 2026)
- “To reflect stronger organic revenue growth, and changes in the M&A and foreign exchange impacts, the company is raising its full-year 2026 guidance for revenue to be between $17,275 million and $17,475 million, for Adjusted EBITDA to be between $4,000 million and $4,050 million and for Adjusted Diluted Earnings per Share to be between $12.80 and $13.00.”
- “The new mid-point of the revenue growth guidance is 6.5% versus the prior guidance of 5.8%, reflecting approximately 100 basis points higher organic revenue growth, and approximately 50 basis points higher contribution from M&A offset by approximately 80 basis points unfavorable change in foreign exchange impact, all versus prior guidance.”
- “This revenue guidance now assumes approximately 200 basis points of contribution from acquisitions versus 150 basis points in the prior guidance and approximately 20 basis points of tailwind from foreign exchange versus 100 basis points tailwind in the prior guidance.”
- “All financial guidance assumes foreign currency exchange rates as of July 27, 2026 remain in effect for the forecast period.”
Quoted word-for-word from the SEC 8-K results press release.
IQV analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $3.28 | $3.25 | +0.8% | $4.37B | 17 |
| Next quarter (ends Dec 2026) | $3.65 | $3.62 | +0.8% | $4.53B | 16 |
| Current fiscal year (ends Dec 2026) | $12.96 | $12.80 | +1.2% | $17.42B | 21 |
| Next fiscal year (ends Dec 2027) | $14.39 | $14.17 | +1.6% | $18.47B | 21 |
Key Statistics (as of October 23, 2026 at 09:23 UTC)
| Price | USD 278.32 |
|---|---|
| Change | ▲ 0.61% (up) |
| Previous Close | USD 278.32 |
| Open | USD 278.32 |
| Day Range | USD 273.8 – 282.98 |
| 52-Week Range | USD 154.5 – 282.98 |
| Volume | 1,672,402 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (IQV)
Nexqual's technical model rates IQV "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 62.95 (neutral) |
| vs SMA50 | Above (USD 262.47) |
| MACD | 3.08 (positive) |
Analyst Ratings (IQV)
Wall Street analysts rate IQV "Buy" based on 21 analysts, with a mean price target of USD 302.67 (range USD 268–345), per Nexqual as of October 23, 2026 at 09:23 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 21 |
| Mean Target | USD 302.67 |
| High Target | USD 345 |
| Low Target | USD 268 |
| Buy / Hold / Sell | 19 / 2 / 0 |
Earnings (IQV)
| Next Earnings Date | 2026-10-27 |
|---|---|
| EPS Estimate | USD 3.28 |
| Revenue Estimate | $4.37B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 3.15 vs est 3.03 ▲ beat |
| 2026-03-31 | USD 2.9 vs est 2.82 ▲ beat |
| 2025-12-31 | USD 3.42 vs est 3.4 ▲ beat |
| 2025-09-30 | USD 3 vs est 2.98 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financials & Fundamentals (IQV)
| Total Revenue | $16.98B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +8.70% |
| Gross Margin | +32.97% |
| Operating Margin | +13.03% |
| Profit Margin | +8.10% |
| ROE | +22.82% |
| Debt / Equity | 2.58 |
| Current Ratio | 0.71 |
| Total Cash | $2.08B |
| Total Debt | $16.25B |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Ownership (IQV)
| Insider Ownership | +1.09% |
|---|---|
| Institutional Ownership | +103.49% |
| Shares Outstanding | 164.60M |
| Float | 156.25M |
| Short % of Float | +2.27% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Leadership (IQV)
IQVIA Holdings Inc. is led by Ari Bousbib, CEO & Chairman, per Nexqual as of October 23, 2026 at 09:23 UTC.
| CEO & Chairman | Ari Bousbib |
|---|---|
| President of Research & Development Solutions | W. Richard Staub |
| President of Commercial Solutions | Alistair Grenfell |
| Executive VP & Chief Financial Officer | Michael J. Fedock |
| Executive Vice President of Global Infrastructure & Operations | James G. Berkshire |
Major Backers & Investors (IQV)
Notable institutional backers of IQVIA Holdings Inc. include Harris Associates L.P., JPMorgan, Artisan Partners Limited Partnership, according to Nexqual as of October 23, 2026 at 09:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Harris Associates L.P. | 7.4% |
| JPMorgan | 3.73% |
| Artisan Partners Limited Partnership | 2.88% |
| Boston Partners | 2.71% |
| Invesco | 1.99% |
| Fidelity | 1.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.19% |
| BlackRock | 8.84% |
| State Street | 4.56% |
| Geode Capital | 2.71% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
From IQVIA Holdings Inc.'s Latest SEC 10-K Filing (filed 2026-02-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Our scaled and growing information set contains approximately 68 petabytes of unique proprietary data sourced from approximately 150,000 data suppliers and covering over one million data feeds globally.
- We combine our proprietary information assets with advanced analytics, transformative technology and domain expertise to develop clinical and commercial capabilities that enable us to grow our relationships with healthcare stakeholders throughout the life science's value chain.
- We compete in a market of approximately $335 billion consisting of outsourced research and development, real-world evidence and connected health and technology enabled clinical and commercial operations markets for life sciences companies and the broader healthcare industry.
- Second, the addressable opportunity for connected healthcare is approximately $55 billion, and includes areas such as revenue cycle management, payer & provider analytics and clinical decision support services. •Technology enabled commercial operations: Total addressable market of approximately $84 billion in 2025 that includes information, data warehousing, IT outsourcing, software applications and other services in the broader market for IT services.
Legal & Regulatory Risks (Item 1A, quoted)
- We may be subject to claims by others that we are infringing on their intellectual property rights.
- Data protection, privacy and similar laws restrict access, use and disclosure of personal information, and failure to comply with these laws could materially harm our business.
- Laws restricting biopharmaceutical sales and marketing practices may adversely impact demand for our services.
- The expectations and requirements of regulators and other key stakeholders on sustainability-related matters, continue to evolve and diverge, and our ability to meet these expectations and requirements could increase our costs, and inaction could harm our reputation and adversely impact our financial results.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| WAT | Waters Corporation | USD 455.59 | ▼ 0.41% |
| IDXX | IDEXX Laboratories, Inc. | USD 566.76 | ▲ 2.4% |
| A | Agilent Technologies, Inc. | USD 173.89 | ▼ 2.17% |
| ILMN | Illumina, Inc. | USD 269.4 | ▼ 4.76% |
| NTRA | Natera, Inc. | USD 401.37 | ▼ 2.91% |
| MTD | Mettler-Toledo International, I | USD 1,684.64 | ▲ 0.4% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt